Address
Email address
Phone number
Website
Name
TALLINNA FARMAATSIATEHASE AKTSIASELTS
Registry code
10093221
VAT number
EE100073649
Type
AS - Joint Stock Company
Status
Registered
Foundation date
16.09.1996 (28)
Financial year
01.01-31.12
Capital
875 000.00 €
Activity
72191 - Other research and experimental development on natural sciences and engineering 47991 - Other retail sale not in stores, stalls or markets 21201 - Manufacture of pharmaceutical preparations
-
-
-
-
-
-
Submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Kadri Randveer 21.12.1973 (50) | - | Board member | - |
| 2019 08.06.2020 | 2020 16.06.2021 | 2021 14.06.2022 | 2022 16.06.2023 | 2023 18.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | - | - | - | 5 075 298 € | - |
| Net profit (loss) for the period | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| Current Assets | - | - | - | - | - |
| Fixed Assets | - | - | - | - | - |
| Total Assets | - | - | - | 10 896 366 € | - |
| Current Liabilities | - | - | - | - | - |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | - | - | - | - | - |
| Equity | - | - | - | - | - |
| Employees | - | - | - | 45 | - |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 1 540 054.53 € | 181 581.07 € | 188 803.81 € | 50 |
| 2023 Q4 | 2 251 599.26 € | 260 990.97 € | 271 713 € | 50 |
| 2023 Q3 | 1 540 195.57 € | 256 674.79 € | 264 204.95 € | 50 |
| 2023 Q2 | 2 003 709.85 € | 160 722.96 € | 167 097.44 € | 51 |
| 2023 Q1 | 1 548 087.49 € | 150 769.75 € | 155 881.31 € | 50 |
| 2022 Q4 | 2 144 972.26 € | 167 727.27 € | 174 322.93 € | 50 |
| 2022 Q3 | 1 541 646.66 € | 271 671.98 € | 280 851.74 € | 52 |
| 2022 Q2 | 1 121 217.1 € | 176 581.7 € | 182 732.69 € | 49 |
| 2022 Q1 | 1 638 042.1 € | 148 411.52 € | 153 562.53 € | 52 |
| 2021 Q4 | 2 294 314.94 € | 151 731.73 € | 156 927.5 € | 54 |
| 2021 Q3 | 1 780 451.41 € | 259 022.41 € | 269 003.85 € | 51 |
| 2021 Q2 | 2 729 016.45 € | 153 502 € | 159 700.7 € | 57 |
| 2021 Q1 | 1 995 211.44 € | 135 587.58 € | 140 621.62 € | 63 |
| 2020 Q4 | 2 580 515.61 € | 159 844.57 € | 166 131.33 € | 52 |
| 2020 Q3 | 1 673 779.29 € | 231 134.04 € | 237 960.97 € | 50 |
| 2020 Q2 | 1 996 451.02 € | 120 582.92 € | 125 375.9 € | 57 |
| 2020 Q1 | 1 211 361.24 € | 142 013.32 € | 147 395.78 € | 49 |
